Serum Albumin Levels in Outpatients Receiving Anti-Cancer Chemotherapy

DOI NDL Digital Collections 13 References
  • Itagaki Fumio
    Department of Pharmacy,Tsukuba University Hospital
  • Kato Hiroyoshi
    Department of Pharmacy,National Cancer Center Hospital East
  • Motonaga Shinya
    Department of Pharmacy,National Cancer Center Hospital East
  • Ichida Yasuhiko
    Department of Pharmacy,National Cancer Center Hospital East
  • Matsui Reiko
    Department of Pharmacy,National Cancer Center Hospital East
  • Endo Kazushi
    Department of Pharmacy,National Cancer Center Hospital East
  • Kambayashi Yasuyuki
    Department of Pharmacy,Tsukuba University Hospital
  • Homma Masato
    Department of Pharmacy,Tsukuba University Hospital Department of Pharmaceutical Sciences,Graduate School of Comprehensive Human Sciences,University of Tsukuba
  • Kohda Yukinao
    Department of Pharmacy,Tsukuba University Hospital Department of Pharmaceutical Sciences,Graduate School of Comprehensive Human Sciences,University of Tsukuba

Bibliographic Information

Other Title
  • がん化学療法を施行した外来患者における血清アルブミン濃度

Search this article

Abstract

As hypoalbuminemia is a risk factor of severe hematological toxicity occurring in anticancer chemotherapy,we examined serum albumin levels in outpatients receiving several different chemotherapy regimens.The data of 4215 samples collected from 946 outpatients receiving anticancer chemotherapy were investigated.Mean (±SD) serum albumin was 3.8±0.4 g/dL with levels in the 2.0-2.9 g/dL,3.0-3.9 g/dL and 4.0-4.9 g/dL accounting for 2.5%,56.6% and 40.9% of the total number of samples,respectively.Serum albumin levels differed by disease and chemotherapy regimen.The mean albumin levels for each chemotherapy regimen were significantly directly correlated with hematocrit (rs=0.752,p<0.01),BMI (rs=0.581,p=0.02)and inversely correlated with age (rs=-0.578,p=0.02).The frequencies of hypoalbuminemia were higher in patients with gastric,pancreatic and esophageal cancer than in patients with breast and colorectal cancer (70.5-91.4% vs.20.3 -63.1%) since the former were older and had a lower BMI.These data suggests that the risk for a severe hematological toxicity and an alteration of pharmacokinetics in highly protein-bound anticancer agents increase in patients with gastric,pancreatic and esophageal cancer.

Journal

References(13)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top